Jounce Therapeutics, Inc.: Nasdaq/NYSE listing notice — Jounce Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Jounce Therapeutics, Inc.

Received Nasdaq deficiency letter on Dec 29, 2022; bid price below $1.00 for 30 consecutive business days.
Has until June 27, 2023 to regain compliance; closing bid must be ≥$1.00 for 10 consecutive business days.
May consider reverse stock split or transfer to Nasdaq Capital Market if not compliant by deadline.
Failure to regain compliance could lead to delisting; appeal rights exist but no assurance of success.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Jounce Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 29, 2022, Jounce Therapeutics, Inc., a Delaware corporation (the “Company”), received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with N

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001640455-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.